Global Blood Cancer Therapeutics Market 2019-2023 | Evolving Opportunities with Novartis AG and Bristol-Myers Squibb Company | Technavio
LONDON--(BUSINESS WIRE)--Jan 14, 2020--
The global blood cancer therapeutics market is poised to grow by USD 12.63 billion during 2019-2023, progressing at a CAGR of over 8% during the forecast period. Request Free Sample Pages
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200114005338/en/
Technavio has announced its latest market research report titled global blood cancer therapeutics market 2019-2023. (Graphic: Business Wire)
Read the 119-page research report with TOC on “Blood Cancer Therapeutics Market Analysis Report by Type (Leukemia, Lymphoma, and Myeloma), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023”.
The growing adoption of therapeutics and the advent of novel therapies are factors anticipated to boost the growth of the market.
Vendors and various organizations are creating awareness about various types of blood cancer through blood cancer awareness campaigns. This prevents delayed diagnosis and treatment of disease. For instance, Janssen Pharmaceuticals, Inc. started Make Blood Cancer Visible program as a part of the Blood Cancer Awareness Month in 2015 to raise awareness about the disease. Such initiatives are encouraging patients to opt for preventative tests and thus seek treatment during the early stages of the disease. Furthermore, vendors and government organizations are introducing patient assistance programs to provide treatment at an affordable cost, thereby increasing patient adherence. Thus, increasing awareness is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Blood Cancer Therapeutics Market Companies:
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is headquartered in the US and operates the business under the BioPharmaceuticals segment. The company offers SPRYCEL, which is a prescription medicine approved for the treatment of chronic myeloid leukemia in adults and pediatric patients.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd is headquartered in Switzerland and offers products through the following business units: Pharmaceuticals and Diagnostics. The company offers RITUXAN, GAZYVA, and VESANOID.
Johnson & Johnson Services, Inc.
Johnson & Johnson Services, Inc. is headquartered in the US and operates under various business segments, namely Consumer, Pharmaceutical, and Medical devices. The company offers DARZALEX and IMBRUVICA.
Novartis AG is headquartered in Switzerland and offers products through the following business segments: Innovative medicines, Sandoz, and Alcon. The company offers ARZERRA, KYMRIAH, GLEEVEC, RYDAPT, and TASIGNA.
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is headquartered in Japan and operates through only one segment which focuses on commercialization of pharmaceutical products. The company offers VELCADE and ICLUSIG.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform
Blood Cancer Therapeutics Type Outlook (Revenue, USD Million, 2019 - 2023)
Blood Cancer Therapeutics Regional Outlook (Revenue, USD Million, 2019 - 2023)
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.Request a free sample report
Related Reports on Health Careinclude:
Artificial Blood Substitutes Market – Global Artificial Blood Substitutes Market by product (HBOC and PFBOC) and geography (Asia, Europe, North America, and ROW).
Blood Grouping Reagents Market – Global Blood Grouping Reagents Market by geography (Asia, Europe, North America, and ROW) and end-user (hospitals and blood banks; clinical laboratories; and academic and research institutes).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200114005338/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Technavio Research
Copyright Business Wire 2020.
PUB: 01/14/2020 05:30 AM/DISC: 01/14/2020 05:30 AM